ValuEngine cut shares of Momenta Pharmaceuticals (NASDAQ:MNTA) from a strong-buy rating to a buy rating in a research report sent to investors on Tuesday.

A number of other research analysts have also recently weighed in on MNTA. Zacks Investment Research upgraded shares of Momenta Pharmaceuticals from a sell rating to a hold rating in a report on Friday, June 22nd. BidaskClub cut shares of Momenta Pharmaceuticals from a buy rating to a hold rating in a report on Saturday, June 23rd. Cantor Fitzgerald set a $24.00 price target on shares of Momenta Pharmaceuticals and gave the stock a hold rating in a report on Thursday, August 9th. Finally, Stifel Nicolaus reiterated a buy rating and set a $40.00 price target on shares of Momenta Pharmaceuticals in a report on Wednesday, October 10th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus price target of $24.25.

MNTA stock traded down $0.24 during trading on Tuesday, reaching $14.50. 4,840 shares of the stock were exchanged, compared to its average volume of 985,964. Momenta Pharmaceuticals has a 1 year low of $11.85 and a 1 year high of $32.20. The company has a market capitalization of $1.18 billion, a PE ratio of -12.06 and a beta of 1.75.

Momenta Pharmaceuticals (NASDAQ:MNTA) last released its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.50). The company had revenue of $13.00 million during the quarter, compared to analysts’ expectations of $15.83 million. Momenta Pharmaceuticals had a negative net margin of 128.49% and a negative return on equity of 40.55%. Momenta Pharmaceuticals’s revenue was down 44.9% on a year-over-year basis. During the same period last year, the firm posted ($0.50) earnings per share. As a group, analysts anticipate that Momenta Pharmaceuticals will post -2.3 earnings per share for the current fiscal year.

In other news, Director Elizabeth Stoner sold 4,152 shares of the company’s stock in a transaction on Monday, August 27th. The shares were sold at an average price of $27.33, for a total value of $113,474.16. Following the completion of the transaction, the director now owns 33,791 shares in the company, valued at approximately $923,508.03. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Craig A. Wheeler sold 1,773 shares of the company’s stock in a transaction on Friday, August 10th. The shares were sold at an average price of $26.06, for a total transaction of $46,204.38. The disclosure for this sale can be found here. In the last 90 days, insiders sold 12,589 shares of company stock valued at $345,785. Company insiders own 4.80% of the company’s stock.

Institutional investors have recently modified their holdings of the company. SG Americas Securities LLC acquired a new position in shares of Momenta Pharmaceuticals in the 2nd quarter valued at $108,000. Essex Investment Management Co. LLC acquired a new position in shares of Momenta Pharmaceuticals in the 3rd quarter valued at $330,000. Amalgamated Bank boosted its holdings in shares of Momenta Pharmaceuticals by 16.1% in the 2nd quarter. Amalgamated Bank now owns 12,544 shares of the biotechnology company’s stock valued at $257,000 after buying an additional 1,739 shares in the last quarter. Laurion Capital Management LP acquired a new position in shares of Momenta Pharmaceuticals in the 2nd quarter valued at $284,000. Finally, Profund Advisors LLC boosted its holdings in shares of Momenta Pharmaceuticals by 33.1% in the 1st quarter. Profund Advisors LLC now owns 15,483 shares of the biotechnology company’s stock valued at $281,000 after buying an additional 3,853 shares in the last quarter. Institutional investors and hedge funds own 95.99% of the company’s stock.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.

Further Reading: Penny Stocks, Risk and Reward Factors

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.